vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.
TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $10.7M, roughly 2.0× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 7.5%, a 16.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 17.7%). Over the past eight quarters, TEJON RANCH CO's revenue compounded faster (68.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.
ABUS vs TRC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $21.1M |
| Net Profit | $2.5M | $1.6M |
| Gross Margin | — | 30.6% |
| Operating Margin | 13.9% | 10.9% |
| Net Margin | 23.5% | 7.5% |
| Revenue YoY | 522.2% | 17.7% |
| Net Profit YoY | 112.7% | -64.7% |
| EPS (diluted) | $0.01 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.1M | ||
| Q3 25 | — | $12.0M | ||
| Q2 25 | $10.7M | $8.3M | ||
| Q1 25 | — | $8.2M | ||
| Q4 24 | — | $17.9M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $5.7M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $1.7M | ||
| Q2 25 | $2.5M | $-1.7M | ||
| Q1 25 | — | $-1.5M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $957.0K | ||
| Q1 24 | — | $-914.0K |
| Q4 25 | — | 30.6% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | — | 45.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | 13.9% | -48.8% | ||
| Q1 25 | — | -50.7% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | -34.9% | ||
| Q2 24 | — | -62.4% | ||
| Q1 24 | — | -53.8% |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | 23.5% | -20.6% | ||
| Q1 25 | — | -17.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | — | -16.9% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | — | -12.3% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | $0.01 | $-0.06 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $0.04 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $9.5M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $475.2M |
| Total Assets | $103.3M | $630.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.5M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $37.4M | $2.5M | ||
| Q1 25 | — | $12.3M | ||
| Q4 24 | — | $39.3M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $35.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $475.2M | ||
| Q3 25 | — | $473.2M | ||
| Q2 25 | $83.0M | $471.5M | ||
| Q1 25 | — | $472.5M | ||
| Q4 24 | — | $473.6M | ||
| Q3 24 | — | $468.3M | ||
| Q2 24 | — | $469.2M | ||
| Q1 24 | — | $467.4M |
| Q4 25 | — | $630.5M | ||
| Q3 25 | — | $629.6M | ||
| Q2 25 | $103.3M | $618.5M | ||
| Q1 25 | — | $614.6M | ||
| Q4 24 | — | $608.0M | ||
| Q3 24 | — | $598.0M | ||
| Q2 24 | — | $590.8M | ||
| Q1 24 | — | $581.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $6.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | 3.88× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | $-15.7M | $-381.0K | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $777.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-14.6M | ||
| Q2 25 | — | $-20.0M | ||
| Q1 25 | — | $-18.9M | ||
| Q4 24 | — | $-42.9M | ||
| Q3 24 | — | $-16.8M | ||
| Q2 24 | — | $-15.8M | ||
| Q1 24 | — | $-7.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | -122.2% | ||
| Q2 25 | — | -240.6% | ||
| Q1 25 | — | -230.1% | ||
| Q4 24 | — | -239.3% | ||
| Q3 24 | — | -155.2% | ||
| Q2 24 | — | -277.2% | ||
| Q1 24 | — | -99.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 102.3% | ||
| Q2 25 | 0.0% | 236.0% | ||
| Q1 25 | — | 213.7% | ||
| Q4 24 | — | 319.1% | ||
| Q3 24 | — | 174.3% | ||
| Q2 24 | — | 245.5% | ||
| Q1 24 | — | 109.5% |
| Q4 25 | — | 3.88× | ||
| Q3 25 | — | -1.43× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.88× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
